- •A predictive model for R0 was developed and validated.
- •Variables included disease score, stage, CA125, ascites, and stage-age interaction.
- •Model alone should not determine management of advanced stage ovarian cancer.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Role of aggressive surgical cytoreduction in advanced ovarian cancer.J. Gynecol. Oncol. 2015; 26: 336-342
- Improved progression free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.Gynecol. Oncol. 2009; 114: 26-31
- Maximal cytoreductive effort in epithelial ovarian cancer surgery.J. Gynecol. Oncol. 2010; 21: 75-80
- What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?.Gynecol. Oncol. 2006; 03: 559-564
- Prognostic factors for advanced epithelial ovarian cancer: a gynecologic oncology group study.J. Clin. Oncol. 2007; 25: 3621-3627
- Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of GOG 182.Gynecol. Oncol. 2013; 130: 487-492
- Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis.Gynecol. Oncol. 2013; 130: 493-498
- Evolution of surgical treatment paradigms for advanced stage ovarian cancer: redefining “optimal” residual disease.Gynecol. Oncol. 2012; 125: 483-492
- Optimal (≤1 cm) but visible residual disease: is extensive debulking warranted?.Gynecol. Oncol. 2013; 130: 284-288
- Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced stage ovarian cancer: an analysis of GOG 182.J. Clin. Oncol. 2015; 33: 937-943
- Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.N. Engl. J. Med. 2010; 363: 943-953
- Miles of agreement and millimeters of controversy.J. Clin. Oncol. 2015; 33: 3521-3522
- A framework for a personalized surgical approach to ovarian cancer.Nat. Rev. Clin. Oncol. 2015; 12: 239-245
- Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup.J. Clin. Oncol. 2009; 27: 1419-1425
- Prognosis and prognostic research: validating a prognostic model.BMJ. 2009; 338: b605
Harrell FE. Springer Series in Statistics: Regression Modeling Strategies (Corrected ed.) 2010; New York, NY: Springer New York. Pg 247.
- Index for rating diagnostic tests.Cancer. 1950; 13: 32-35
- Regression modeling strategies for improved prognostic prediction.Stat. Med. 1984; 3: 143-152
- Multivariable prognostic models: issues in developing models, evaluating assumptions, and adequacy, and measuring and reducing errors.Stat. Med. 1996; 15: 361-387
- A model for predicting surgical outcome in patients with advanced epithelial ovarian carcinoma using computed tomography.Cancer. 2000; 89: 1532-1540
- Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer.J. Clin. Oncol. 2007; 25: 384-389
- A multicenter validation of computerized tomography models as predictors of non-optimal primary cytoreduction of advanced epithelial ovarian cancer.Eur. J. Surg. Oncol. 2009; 35: 1109-1112
- To predict or not to predict? The dilemma of predicting the risk of suboptimal cytoreduction in ovarian cancer.Ann. Oncol. 2011; 22 (Dec): viii23-viii28
- The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma.Cancer. 2004; 101: 346-352
- Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial.Br. J. Cancer. 2009; 101: 1066-1073
- Prediction of incomplete primary debulking surgery in patients with advanced ovarian cancer: an external validation study of three models using computed tomography.Gynecol. Oncol. 2016; 140: 22-28
- A multi-center prospective trial evaluating the ability of preoperative computed tomography scan and serum CA125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.Gynecol. Oncol. 2014; 134: 455-461
- Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer.Gynecol. Oncol. 2015; 138: 70-77
- Discrepancy between preoperative imaging and surgical findings in patients with advanced ovarian cancer: a study of initial false-negative lesions.J. Comput. Assist. Tomogr. 2013; 37: 568-571
- Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept.Gynecol. Oncol. 2015; 139: 5-9
- Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicenter randomized controlled study.BMC Cancer. 2012; 12: 31
- Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples.J. Natl. Cancer Inst. 2014; 106
☆Presented in part at the Society of Gynecologic Oncology (SGO) 2014 Annual Meeting on Women's Cancer, March 28–1 April, 2014, Tampa FL.
☆☆The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of Defense.
★This study was supported by the National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office ( CA 27469 ), the Gynecologic Oncology Group Statistical Office ( CA 37517 ), NRG Oncology SDMC ( 1U10 CA180822 ) and NRG Operations ( U10CA180868 ). The following Gynecologic Oncology Group member institutions participated in the primary treatment studies: University of Alabama at Birmingham, Oregon Health Sciences University, Duke University Medical Center, Abington Memorial Hospital, University of Rochester Medical Center, Walter Reed Army Medical Center, Wayne State University, University of Minnesota Medical School, University of Southern California at Los Angeles, University of Mississippi Medical Center, Colorado Gynecologic Oncology Group P.C., University of California at Los Angeles, University of Washington, University of Pennsylvania Cancer Center, University of Miami School of Medicine, Milton S. Hershey Medical Center, Georgetown University Hospital, University of Cincinnati, University of North Carolina School of Medicine, University of Iowa Hospitals and Clinics, University of Texas Southwestern Medical Center at Dallas, Indiana University School of Medicine, Wake Forest University School of Medicine, Albany Medical College, University of California Medical Center at Irvine, Tufts-New England Medical Center, Rush-Presbyterian-St. Luke's Medical Center, University of Kentucky, Eastern Virginia Medical School, The Cleveland Clinic Foundation, Johns Hopkins Oncology Center, State University of New York at Stony Brook, Eastern Pennsylvania GYN/ONC Center, P.C., Southwestern Oncology Group, Washington University School of Medicine, Memorial Sloan-Kettering Cancer Center, Columbus Cancer Council, University of Massachusetts Medical School, Fox Chase Cancer Center, Medical University of South Carolina, Women's Cancer Center, University of Oklahoma, University of Virginia Health Sciences Center, University of Chicago, University of Arizona Health Science Center, Tacoma General Hospital, Eastern Collaborative Oncology Group, Thomas Jefferson University Hospital, Case Western Reserve University, and Tampa Bay Cancer Consortium.